Cerapedics recalled 237 units of PearMatrix P-15 Peptide Enhanced Bone Graft on December 29, 2025. The recall affects products distributed nationwide after a review revealed incorrect expiration dates. Patients and healthcare providers should stop using the product immediately.
Incorrect expiration date
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Cerapedics, Inc. or your healthcare provider for instructions. Notification method: E-Mail
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is PearMatrix P-15 Peptide Enhanced Bone Graft, 1.0cc, REF: 730-010. It was distributed nationwide in the United States, including states such as California and New York. The recall involves 237 units.
The recall was initiated due to incorrect expiration dates on the product, potentially compromising its effectiveness. Using a bone graft beyond its expiration date poses health risks for patients undergoing procedures.
There are no reported injuries or incidents associated with this product at the time of the recall. However, the incorrect expiration date raises concerns about patient safety.
Patients and healthcare providers should stop using the affected product immediately. They should contact Cerapedics, Inc. or their healthcare provider for further instructions regarding the recall.
For more information, contact Cerapedics, Inc. via email. Additional details are available on the FDA's website at the provided link.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.